Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, and Novellus Biopharma AG (Novellus) announced today a strategic partnership for the development and commercialization of KALBITOR ® (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. KALBITOR is marketed in United States for the treatment of acute attacks of HAE in patients 16 years of age and older.
Under the terms of the exclusive license agreement, Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of KALBITOR in the covered territories. Additionally, Novellus will purchase drug product from Dyax on a cost-plus basis for commercial supply.
"We are pleased to announce a new partnership for KALBITOR in Latin America, and look forward to working with Novellus toward its commercialization in this region,” said Gustav Christensen, President and Chief Executive Officer of Dyax Corp. “Novellus’ experience in bringing novel biotherapeutics to market will be important in delivering KALBITOR to HAE patients in this region. We continue to make strides in expanding the availability of KALBITOR and delivering an acute HAE treatment to patients in need around the globe."
“Based on the clinical and commercial success of KALBITOR as an acute treatment for HAE in the United States, we are excited to bring this important therapeutic to the Latin American market,” commented David Muñoz Guzman, Chief Executive Officer of Novellus. “We believe there is a great opportunity in Latin America to provide solutions for the management of HAE and we look forward to working with Dyax to bring KALBITOR to these markets.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts